Valproate reduced excitatory postsynaptic currents in hippocampal CA1 pyramidal neurons

Neuropharmacology

Volumn 46, Issue 4, 2004, Pages 555-561

  Martín, Eduardo D ^a,b   Pozo, Miguel A ^b  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Excitatory synaptic activity; Hippocampal slices; Postsynaptic regulation; Valproate

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID; VALPROIC ACID;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; INHIBITORY POSTSYNAPTIC POTENTIAL; NERVE STIMULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PATCH CLAMP; PERFUSION; PRIORITY JOURNAL; PROBABILITY; PYRAMIDAL NERVE CELL; RAT; SYNAPSE; SYNAPTIC TRANSMISSION;

EID: 1242351257     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.10.013     Document Type: Article

References (30)

1. Alkadhi K.A., Banks F.W. Pre- and postsynaptic actions of valproic acid at the frog neuromuscular junction. Brain Research. 306:1984;388-390.
2. Bekkers J.M., Stevens C.F. Presynaptic mechanism for long-term potentiation in the hippocampus. Nature. 346:1990;724-729.
3. Bowden C.L. Role of newer medications for bipolar disorder. Journal of Clinical Psychopharmacology. 16:1996;48S-55S.
4. Clark K.A., Randall A.D., Collingridge G.L. A comparison of paired-pulsed facilitation of AMPA and NMDA receptor-mediated excitatory postsynaptic currents in the hippocampus. Experimental Brain Research. 101:1994;272-278.
5. Collingridge G.L., Kehl S.J., Mclennan H. Excitatory amino acids in synaptic transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. Journal of Physiology. 334:1983;33-46.
6. Creager R., Dunwiddie T., Lynch G. Paired-pulse and frequency facilitation in the CA1 region of the in vitro rat hippocampus. Journal of Physiology (London). 299:1980;409-424.
7. Crowder J.M., Bradford H.F. Common anticonvulsants inhibit Ca2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia. 28:1987;378-382.
8. Cutrer F.M., Moskowitz M.A. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache. 36:1996;579-585.
9. Fohlmeister J.F., Adelman W.J. Jr., Brennan J.J. Excitable channel currents and gating times in the presence of anticonvulsants ethosuximide and valproate. Journal of Pharmacology and Experimental Therapeutics. 230:1984;75-81.
10. o in the hippocampal slice. Brain Research. 386:1986;1-11.
11. Ghose K., Niven B. Prophylactic sodium valproate therapy in patients with drug-resistant migraine. Methods and Findings in Experimental and Clinical Pharmacology. 20:1998;353-359.
12. Godin Y., Heiner L., Mark J., Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. Journal of Neurochemistry. 16:1969;869-873.
13. Griffith W.H., Taylor L. Sodium valproate decreases synaptic potentiation and epileptiform activity in hippocampus. Brain Research. 474:1988;155-164.
14. Hestrin S., Nicoll R.A., Perkel D.J., Sah P. Analysis of excitatory synaptic action in pyramidal cells using whole-cell recording from rat hippocampal slices. Journal of Physiology. 422:1990;203-225.
15. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochemistry International. 37:2000;103-110.
16. Löscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Research. 501:1989;198-203.
17. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progress in Neurobiology. 58:1999;31-59.
18. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 16:2002;669-694.
19. McLean M.J., Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. Journal of Pharmacology and Experimental Therapeutics. 237:1986;1001-1011.
20. Malinow R., Tsien R.W. Presynaptic enhancement shown by whole-cell recordings of long-term potentiation in hippocampal slices. Nature. 346:1990;177-180.
21. + current in hippocampal CA1 pyramidal neurons: implication in epileptogenesis. Journal of Neurophysiology. 86:2001;2878-2886.
22. Martín E.D., Buño W. Caffeine-mediated presynaptic long-term potentiation in hippocampal CA1 pyramidal neurons. Journal of Neurophysiology. 89:2003;3029-3038.
23. Martín, E.D., Pozo, M.A., 2003. Valproate suppress status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. Epilepsia 44, 1375-1379.
24. McElroy S.L., Keck P.E. Jr., Pope H.G. Jr., Hudson J.I. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. Journal of Clinical Psychopharmacolgy. 12:1992;42S-52S.
25. Perreault P., Tancredi V., Avoli M. Failure of the antiepileptic drug valproic acid to modify synaptic and non-synaptic responses of CA1 hippocampal pyramidal cells maintained 'in vitro'. Epilepsy Research. 3:1989;227-231.
26. Schechter P.J., Tranier Y., Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: correlations with anti-convulsant activity. Journal of Neurochemistry. 31:1978;1325-1327.
27. Slater G.E., Johnston D. Sodium valproate increases potassium conductance in Aplysia neurons. Epilepsia. 19:1978;379-384.
28. VanDongen A.M., VanErp M.G., Voskuyl R.A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia. 27:1986;177-182.
29. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature. 417:2002;292-295.
30. Zeise M.L., Kasparow S., Zieglgansberger W. Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Research. 544:1991;345-348.